| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.20(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
136,870 |
194,989 |
260,525 |
524,601 |
| Total Sell Value |
$2,679,704 |
$3,814,194 |
$5,546,549 |
$13,449,119 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
19 |
38 |
75 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ho Carole |
Chief Medical Officer |
• – – |
2022-08-19 |
4 |
S |
$33.22 |
$85,575 |
I/I |
(2,576) |
173,087 |
|
16% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2022-08-19 |
4 |
S |
$33.22 |
$85,575 |
I/I |
(2,576) |
467,471 |
|
16% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2022-08-19 |
4 |
S |
$33.22 |
$79,861 |
I/I |
(2,404) |
2,202,993 |
|
16% |
|
| Krognes Steve E. |
Director |
– • – |
2022-08-19 |
4 |
S |
$33.22 |
$74,845 |
D/D |
(2,253) |
149,468 |
|
16% |
|
| Schuth Alexander O. |
COFO and Secretary |
• – – |
2022-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
121,458 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2022-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
110,597 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-07-25 |
4 |
S |
$35.60 |
$712,110 |
D/D |
(20,000) |
1,950,356 |
|
12% |
|
| Krognes Steve E. |
Director |
– • – |
2022-07-19 |
4 |
OE |
$0.68 |
$42,500 |
D/D |
62,500 |
151,721 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-06-24 |
4 |
D |
$30.53 |
$1,430,968 |
D/D |
(46,750) |
1,970,356 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-06-23 |
4 |
D |
$31.10 |
$412,076 |
D/D |
(13,250) |
2,017,106 |
|
- |
|
| Flatley Jay T |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
5,986 |
336,313 |
|
- |
|
| Cole Douglas G. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
22,348 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
11,313 |
|
- |
|
| Klein Peter S |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
11,313 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
142,149 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
11,313 |
|
- |
|
| Thornberry Nancy |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
8,497 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
2,030,356 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-03-23 |
4 |
S |
$33.40 |
$676,583 |
D/D |
(20,000) |
2,024,370 |
|
1% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2022-02-11 |
4 |
S |
$34.71 |
$101,284 |
I/I |
(2,918) |
170,663 |
|
13% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2022-02-11 |
4 |
S |
$34.72 |
$329,528 |
I/I |
(9,491) |
2,129,648 |
|
13% |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2022-02-11 |
4 |
S |
$34.69 |
$88,806 |
D/D |
(2,560) |
120,221 |
|
13% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2022-02-11 |
4 |
S |
$34.68 |
$97,208 |
I/I |
(2,803) |
465,047 |
|
13% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2022-02-10 |
4 |
OE |
$5.28 |
$399,984 |
D/D |
70,749 |
260,640 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2022-02-09 |
4 |
S |
$37.10 |
$52,800 |
I/I |
(1,423) |
460,564 |
|
30% |
|
416 Records found
|
|
Page 5 of 17 |
|
|
0.36 (1.93%) 
